Multidimensional Treatment Strategies and Future Prospects of Benign Prostatic Hyperplasia
Abstract
Objective: Benign prostatic hyperplasia (BPH) is a high-risk disease in elderly men, and its incidence continues to rise with aging. Traditional western medicine treatment has a bottleneck in efficacy and a risk of adverse reactions. This article systematically reviews the pathogenesis and clinical treatment of BPH, focusing on the combination of Chinese and Western medicine treatment strategies. Results: The pathogenesis is the imbalance of sex hormones and the abnormal activation of growth factors, which jointly drive the proliferation of prostate cells. In the treatment of western medicine, although -receptor blockers can quickly improve symptoms, they can easily cause dizziness and hypotension. 5- reductase inhibitors reduce prostate volume, but there are limitations such as insufficient short-term efficacy and increased nocturia. In terms of combined treatment of traditional Chinese and Western medicine, the clinical effective rate of Huang 'e capsule combined with tamsulosin/dutasteride increased to 68.13 %. Qianlie Shutong capsule combined with western medicine, can improve bladder function, which is better than single western medicine treatment. Conclusion: The combination of Chinese and Western medicine provides a new path for BPH to enhance efficacy and reduce toxicity. In the future, it is necessary to deeply analyze the targets of active components of traditional Chinese medicine (TCM) and establish a standardized joint program.
Read the paper
Related studies
- Pathophysiology of Overactive Bladder and Pharmacologic Treatments Including β3-Adrenoceptor Agonists -Basic Research Perspectives-
- Exosomal Liquid Biopsy in Prostate Cancer: A Systematic Review of Biomarkers for Diagnosis, Prognosis, and Treatment Response
- Leveraging glycosylation for early detection and therapeutic target discovery in pancreatic cancer
- Rethinking of phosphodiesterase 5 inhibition: the old, the new and the perspective in human health
- Long-term outcomes after treatment with Optilume BPH: Four-year results from the EVEREST study
- Future aspects of plant derived bioactive metabolites as therapeutics to combat benign prostatic hyperplasia
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.